The Effect of Sumac and a Low-Calorie Diet on Improving Fatty Liver Disease

Comparison of the effects of Sumac supplementation plus calorie-restricted diet versus calorie-restricted diet alone on inflammatory markers, oxidative stress, and fasting blood glucose in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250527065918N1

Enrollment

Registered

2025-08-31

Start date

2025-09-21

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver. Other inflammatory liver diseases

Interventions

Intervention 1: Intervention group: 1500 mg of Sumac powder supplement daily in three divided doses of 500 mg for 12 weeks. Intervention 2: Control group: 500 mg daily of placebo (corn starch) with a

Eligibility

Sex/Gender

All

Age

20 Years to 60 Months

Inclusion criteria

Inclusion criteria: Individuals aged 20 to 60 years Presence of fat accumulation in liver ultrasound evaluation with Grade 2 fatty liver and elevated liver enzymes (ALT and AST > 40) Ability to read and write Body Mass Index (BMI) greater than 25 kg/m²

Exclusion criteria

Exclusion criteria: Having chronic lung diseases, other liver diseases, heart conditions, and any chronic kidney or digestive disease History of drinking alcoholic beverages Smoking and drug abuse Use of diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs), estrogen, tamoxifen, corticosteroids, and blood sugar-lowering drugs within 3 weeks before the start of the study and during the study Evidence of viral hepatitis infection Pregnancy Breast feeding Follow of special diet Regular consumption of antioxidant supplements such as vitamins E, C, and silymarin

Design outcomes

Primary

Measure	Time frame
Oxidative stress status (MDA). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Blood glucose. Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: Biochemical kit.;C reactive protein. Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Tumor Necrosis Factor alpha (TNF-a). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Interleukin 10 (IL-10). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Total antioxidant capacity (TAC). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.	—

Measure

Time frame

Oxidative stress status (MDA). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Blood glucose. Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: Biochemical kit.;C reactive protein. Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Tumor Necrosis Factor alpha (TNF-a). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Interleukin 10 (IL-10). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.;Total antioxidant capacity (TAC). Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: ELISA Kit.

—

Secondary

Measure	Time frame
Alanine aminotransferase. Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: Biochemical kit.;Aspartate aminotransferase. Timepoint: Initially and 12 weeks (84 days) after starting sumac supplementation. Method of measurement: Biochemical kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElyas Nattagh Eshtivani

Gonabad University of Medical Sciences

nattagh.elyas@gmail.com+98 51 5722 5027

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026